Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096039 · ClinicalTrials.gov registry record
Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,614,719
- Enrollment target
NCT05096039 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,614,719 participants.
The verdict
NCT05096039 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,614,719 participants
- Enrollment target
Study Summary
This study evaluated the association between sacubitril/valsartan utilization and HF patients' Part A \& B expenditures within the reimbursement framework of BPCI and MSSP, and identified BPCI/MSSP participants with the greatest potential for performance improvement (with respect to improving quality and efficiency of care for HF patients) through optimized utilization of sacubitril/valsartan.
Interventions
- DRUG Sacubitril/valsartan
- DRUG ACEI or ARB and no sacubitril/valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,614,719 participants |
| Start Date | 2020-04-10 |
| Est. Completion | 2020-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05096039
The ClinicalTrials.gov registry entry for NCT05096039 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,614,719 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sacubitril/valsartan is the first listed.
NCT05096039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05096039 about?
NCT05096039 is a clinical study titled "Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models". This study evaluated the association between sacubitril/valsartan utilization and HF patients' Part A \& B expenditures within the reimbursement framework of BPCI and MSSP, and identified BPCI/MSSP participants with the greatest potential for performance improvement (with respect to improving qualit...
What is the current status of trial NCT05096039?
This trial is currently completed. The enrollment target is 1,614,719 participants. The study started on 2020-04-10. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT05096039?
The interventions under investigation include: Sacubitril/valsartan (DRUG), ACEI or ARB and no sacubitril/valsartan (DRUG).
Who is sponsoring clinical trial NCT05096039?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.